



Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS statin literature update will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications May 2021

Add on treatments

1. Tan H, Liu L, Zheng Q *et al.* Effects of Combined Lipid-Lowering Therapy on Low-Density Lipoprotein Cholesterol Variability and Cardiovascular Adverse Events in Patients with Acute Coronary Syndrome. *Adv Ther* 2021; 38:3389-3398. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34018147>
2. Fan H, Zhou J, Yuan Z. Meta-Analysis Comparing the Effect of Combined Omega-3 + Statin Therapy Versus Statin Therapy Alone on Coronary Artery Plaques. *Am J Cardiol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34049675>
3. Lopez DS, Huang D, Tsilidis KK *et al.* The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer. *Cancer Causes Control* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34041642>
4. Sabanis N, Paschou E, Drylli A *et al.* Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt. *CEN Case Rep* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34028728>

5. Domech CR, Travieso JCF, Guridi ZD *et al.* Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol 2021; 7:55-65. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34027116>
6. López-Miranda J, Pedro-Botet J. Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needs. Clin Investig Arterioscler 2021; 33 Suppl 1:46-52. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966813>
7. Jhaveri A, Sibley RA, Spatz ES, Dodson J. Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty. Current cardiology reports 2021; 23:67. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33961154>
8. R CV, Rajkumar Y, Vetriselvan P *et al.* Resveratrol-mediated cardioprotection against myocardial ischemia-reperfusion injury was revoked by statin-induced mitochondrial alterations. Drug and chemical toxicology 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34039170>
9. Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside. Drug design, development and therapy 2021; 15:1955-1963. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34007155>
10. Bosch J, Lonn EM, Jung H *et al.* Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33963372>
11. Olesen KKW, Heide-Jørgensen U, Thim T *et al.* Statin but not Aspirin Treatment is Associated with Reduced Cardiovascular Risk in Patients with Diabetes without Obstructive Coronary Artery Disease. European heart journal. Cardiovascular pharmacotherapy 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33989394>
12. Barrios V, Escobar C. Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesterolemia according to cardiovascular risk. Expert Rev Clin Pharmacol 2021:1-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33970743>
13. Anno T, Yamatsuji T, Tomoda K *et al.* Case Report: Various Abnormalities in Lipid and Glucose Metabolism Induced by Capecitabine. Frontiers in oncology 2021; 11:664475. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34017685>
14. Hu Z, Cheng C, Wang Y *et al.* Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. Frontiers in oncology 2021; 11:595285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34041015>
15. Li Z, Lyu Y, Zhao J *et al.* Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and Gardenia jasminoides J. Ellis. Frontiers in pharmacology 2021; 12:622040. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33967756>
16. Satani N, Zhang X, Giridhar K *et al.* A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro. Frontiers in pharmacology 2021; 12:589418. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33959001>

17. Nakayama A, Morita H, Kawahara T *et al.* Association between testosterone and lipid profiles under statin therapy and its clinical impact on the cardiovascular event risk. Heart Vessels 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34036416>
18. Hitchen SA, Lan NSR, Ali US *et al.* Investigating the effect of an education program on diabetes and lipid lowering medication usage following coronary artery bypass graft surgery. Internal medicine journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34033208>
19. Wei H, Xin X, Zhang J *et al.* Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis of randomized controlled trials. Irish journal of medical science 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33999383>
20. Selvaraj S, Claggett BL, Packer M *et al.* Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure with Preserved Ejection Fraction. J Am Heart Assoc 2021:e022069. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998278>
21. Imre E, Gunhan HG, Erel P, Ustay O. SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study. Minerva Endocrinol (Torino) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33979071>
22. Škorňová I, Samoš M, Bolek T *et al.* Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation? Pharmacol Res Perspect 2021; 9:e00730. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33984191>
23. Patel O, Muller CJF, Joubert E *et al.* Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice. PLoS One 2021; 16:e0251069. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33983968>
24. Bosch J, Lonn EM, Dagenais GR *et al.* Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke 2021:Strokeaha120030790. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33985364>

Adherence

1. Kim SW, Chen J, Wegener KJ *et al.* Improvement of Statin Utilization in Veterans With Diabetes Through Pharmacy Interventions. Clin Diabetes 2021; 39:215-219. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33981132>
2. Mostaza JM, Lahoz C. Main barriers in the management of dyslipidaemias: Intolerants. Clin Investiq Arterioscler 2021; 33 Suppl 1:40-45. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966812>
3. Camila de Souza Groia Veloso R, Cruzeiro MGM, Dias BM, Reis AMM. Assessment of adherence to statin therapy in patients with coronary artery disease: comparison of three self-reporting measures. Eur J Hosp Pharm 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34031152>
4. S WC, G KG, B ME. Assessment of Patient Education about Statin Therapy on Quality Measures and Knowledge in an Independent Community Pharmacy. Innov Pharm 2019; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34007557>

5. Feger S, Elzenbeck L, Rieckmann N *et al.* Effect of Computed Tomography Versus Invasive Coronary Angiography on Statin Adherence: A Randomized Controlled Trial. JACC. Cardiovascular imaging 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34023253>
6. Barankay I, Reese PP, Putt ME *et al.* Qualitative Exploration of Barriers to Statin Adherence and Lipid Control: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open 2021; 4:e219211.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33944923>
7. Hare AJ, Adusumalli S, Park S, Patel MS. Assessment of Primary Care Appointment Times and Appropriate Prescribing of Statins for At-Risk Patients. JAMA network open 2021; 4:e219050. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33974057>
8. Alalaqi A, Lawson G, Obaid Y, Tanna S. Adherence to cardiovascular pharmacotherapy by patients in Iraq: A mixed methods assessment using quantitative dried blood spot analysis and the 8-item Morisky Medication Adherence Scale. PLoS One 2021; 16:e0251115.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33989336>

Atherosclerosis & Imaging

1. Lin TH, Lee WL, Lee WJ *et al.* Dyslipidemia, Not Inflammatory Markers or Adipokines, Contributes Significantly to a Higher SYNTAX Score in Stable Coronary Artery Disease (from the Taichung CAD Study). Acta Cardiologica Sinica 2021; 37:232-238. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33976506>
2. Zanchin C, Koskinas KC, Ueki Y *et al.* Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. Am Heart J 2021; 238:33-44. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33951415>
3. Fan H, Zhou J, Yuan Z. Meta-Analysis Comparing the Effect of Combined Omega-3 + Statin Therapy Versus Statin Therapy Alone on Coronary Artery Plaques. Am J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34049675>
4. Grundy SM, Stone NJ. Coronary Artery Calcium: Where Do We Stand after over three Decades? Am J Med 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34019857>
5. Cao J, Remaley AT, Guan W *et al.* Performance of novel low-density lipoprotein-cholesterol calculation methods in predicting clinical and subclinical atherosclerotic cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2021; 327:1-4.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34004482>
6. Golub I, Lakshmanan S, Dahal S, Budoff MJ. Utilizing coronary artery calcium to guide statin use. Atherosclerosis 2021; 326:17-24.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34000565>
7. Lepor NE, Sun J, Canton G *et al.* Regression in carotid plaque lipid content and neovasculation with PCSK9 inhibition: A time course study. Atherosclerosis 2021; 327:31-38. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34038761>

8. Reeskamp LF, Nurmohamed NS, Bom MJ *et al.* Marked plaque regression in homozygous familial hypercholesterolemia. *Atherosclerosis* 2021; 327:13-17. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34004483>
9. Piri R, Lici G, Riyahimanesh P *et al.* Two-year change in 18F-sodium fluoride uptake in major arteries of healthy subjects and angina pectoris patients. *The international journal of cardiovascular imaging* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33950330>
10. Liu K, Wilkins JT, Colangelo LA, Lloyd-Jones DM. Does Lowering Low-Density Lipoprotein Cholesterol With Statin Restore Low Risk in Middle-Aged Adults? Analysis of the Observational MESA Study. *J Am Heart Assoc* 2021; 10:e019695. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998284>
11. Kanda D, Miyata M, Ikeda Y *et al.* The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins. *J Atheroscler Thromb* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34039817>
12. Komatsu T, Ayaori M, Uto-Kondo H *et al.* Atorvastatin Reduces Circulating S100A12 Levels in Patients with Carotid Atherosclerotic Plaques - A Link with Plaque Inflammation. *J Atheroscler Thromb* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33952812>
13. Lee SH, Shin HS, Oh I. The Protective Effects of Statins Towards Vessel Wall Injury Caused by a Stent Retrieving Mechanical Thrombectomy Device : A Histological Analysis of the Rabbit Carotid Artery Model. *Journal of Korean Neurosurgical Society* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33985322>
14. Feger S, Elzenbeck L, Rieckmann N *et al.* Effect of Computed Tomography Versus Invasive Coronary Angiography on Statin Adherence: A Randomized Controlled Trial. *JACC. Cardiovascular imaging* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34023253>
15. Yao H, Farnier M, Tribouillard L *et al.* Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey. *Lipids Health Dis* 2021; 20:45. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33947397>
16. Huang Q, Wang WT, Wang SS *et al.* Cardiovascular magnetic resonance image analysis and mechanism study for the changes after treatments for primary microvascular angina pectoris. *Medicine (Baltimore)* 2021; 100:e26038. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34032727>
17. Wang J, Weng J, Li H *et al.* Atorvastatin and growth, rupture of small unruptured intracranial aneurysm: results of a prospective cohort study. *Therapeutic advances in neurological disorders* 2021; 14:1756286420987939. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953800>

Atorvastatin/Rosuvastatin

1. Aldosari BN, Almurshedi AS, Alfagih IM *et al.* Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability

- Study. AAPS PharmSciTech 2021; 22:161.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34031791>
2. Sabanis N, Paschou E, Drylli A *et al.* Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt. CEN Case Rep 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34028728>
 3. Barreto GE, Gonzalez J, Reiner Ž *et al.* In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). Chemico-biological interactions 2021:109528.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34022192>
 4. Jeong IG, Lim B, Yun SC *et al.* Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial. Clin Cancer Res 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34011557>
 5. Bravo M, Raurell I, Barberá A *et al.* Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH. Disease models & mechanisms 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34014280>
 6. de Barros JWF, Villela ESP, da Silva GV *et al.* Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects. Drug and chemical toxicology 2021:1-13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33934680>
 7. Barrios V, Escobar C. Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesterolemia according to cardiovascular risk. Expert Rev Clin Pharmacol 2021:1-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33970743>
 8. Ooi BNS, Raechell, Ying AF *et al.* Robust Performance of Potentially Functional SNPs in Machine Learning Models for the Prediction of Atorvastatin-Induced Myalgia. Frontiers in pharmacology 2021; 12:605764.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33967749>
 9. Satani N, Zhang X, Giridhar K *et al.* A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro. Frontiers in pharmacology 2021; 12:589418.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33959001>
 10. Ghafarzadeh M, Shakarami A, Yari F, Marzban Rad Z. The role of anti-proliferative effects of atorvastatin on uterine fibroids: findings from a clinical study. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2021:1-4.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33960277>
 11. Komatsu T, Ayaori M, Uto-Kondo H *et al.* Atorvastatin Reduces Circulating S100A12 Levels in Patients with Carotid Atherosclerotic Plaques - A Link with Plaque Inflammation. J Atheroscler Thromb 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33952812>
 12. Saha A, Garg A. Severe Liver Injury Associated With High-Dose Atorvastatin Therapy. Journal of investigative medicine high impact case reports 2021; 9:23247096211014050. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966478>
 13. Yoshida K, Uwano I, Sasaki M *et al.* Small Unruptured Aneurysm Verification-prevention Effect against Growth of Cerebral Aneurysm Study Using Statin. Neurol Med Chir (Tokyo) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34024878>

14. Krysiak R, Szkróbka W, Okopień B. Correction to: The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome. Pharmacological reports : PR 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34036550>
15. Škorňová I, Samoš M, Bolek T *et al.* Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation? Pharmacol Res Perspect 2021; 9:e00730. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33984191>
16. Patel O, Muller CJF, Joubert E *et al.* Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice. PLoS One 2021; 16:e0251069.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33983968>
17. Wang J, Weng J, Li H *et al.* Atorvastatin and growth, rupture of small unruptured intracranial aneurysm: results of a prospective cohort study. Therapeutic advances in neurological disorders 2021; 14:1756286420987939.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33953800>

Basic science

1. Aldosari BN, Almurshedi AS, Alfagih IM *et al.* Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study. AAPS PharmSciTech 2021; 22:161.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34031791>
2. Kocak E, Nemutlu E, Kir S *et al.* Integrative proteomics and metabolomics approach to elucidate the antimicrobial effect of simvastatin on Escherichia coli. Biomedical chromatography : BMC 2021:e5180.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34043824>
3. Valencia DY, Habila M, McClelland DJ *et al.* Infection-associated biofilms and statins: protocol for systematic review. BMJ Open 2021; 11:e046290.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34035102>
4. Akoulina EA, Demianova IV, Zharkova, Il *et al.* Growth of Mesenchymal Stem Cells on Poly(3-Hydroxybutyrate) Scaffolds Loaded with Simvastatin. Bulletin of experimental biology and medicine 2021; 171:172-177.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34046794>
5. Barreto GE, Gonzalez J, Reiner Ž *et al.* In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). Chemico-biological interactions 2021:109528.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34022192>
6. Bartkowiak A, Matyszewska D, Krzak A *et al.* Incorporation of simvastatin into lipid membranes: Why deliver a statin in form of inclusion complex with hydrophilic cyclodextrin. Colloids and surfaces. B, Biointerfaces 2021; 204:111784.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33984617>
7. Bravo M, Raurell I, Barberá A *et al.* Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH. Disease models & mechanisms 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34014280>

8. de Barros JWF, Villela ESP, da Silva GV *et al.* Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects. Drug and chemical toxicology 2021:1-13.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33934680>
9. R CV, Rajkumar Y, Vetrivelan P *et al.* Resveratrol-mediated cardioprotection against myocardial ischemia-reperfusion injury was revoked by statin-induced mitochondrial alterations. Drug and chemical toxicology 2021:1-9.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34039170>
10. Filppula AM, Hirvensalo P, Parviainen H *et al.* Comparative hepatic and intestinal metabolism and pharmacodynamics of statins. Drug metabolism and disposition: the biological fate of chemicals 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34045219>
11. Rahmani Z, Karimpour Malekshah A, Zargari M, Talebpour Amiri F. Effect of prenatal exposure to Benzo(a)pyrene on ovarian toxicity and reproductive dysfunction: Protective effect of atorvastatin in the embryonic period. Environ Toxicol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33978294>
12. Gao X, Zhou J, Bian Y *et al.* Simvastatin intervention mitigates hypercholesterolemia-induced alveolar bone resorption in rats. Experimental and therapeutic medicine 2021; 21:628.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33936284>
13. Yu D, Huang C, Jiang C, Zhu H. Features of a simvastatin-loaded multi-layered co-electrospun barrier membrane for guided bone regeneration. Experimental and therapeutic medicine 2021; 22:713.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34007322>
14. Møller PL, Rohde PD, Winther S *et al.* Sortilin as a Biomarker for Cardiovascular Disease Revisited. Frontiers in cardiovascular medicine 2021; 8:652584.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33937362>
15. Hu Z, Cheng C, Wang Y *et al.* Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. Frontiers in oncology 2021; 11:595285.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34041015>
16. Huang X, He W, Wang W *et al.* Toxicology and Pharmacokinetics Study of Intradiscal Injection of Simvastatin in Rabbits. Frontiers in pharmacology 2021; 12:582309. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33967746>
17. Li Z, Lyu Y, Zhao J *et al.* Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Co-administered With Simvastatin and Gardenia jasminoides J. Ellis. Frontiers in pharmacology 2021; 12:622040.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33967756>
18. Satani N, Zhang X, Giridhar K *et al.* A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro. Frontiers in pharmacology 2021; 12:589418.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33959001>
19. Zhang Y, Ma L, Lu E, Huang W. Atorvastatin Upregulates microRNA-186 and Inhibits the TLR4-Mediated MAPKs/NF- κ B Pathway to Relieve Steroid-Induced Avascular

- Necrosis of the Femoral Head. Frontiers in pharmacology 2021; 12:583975. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33995003>
20. Santarelli R, Pompili C, Gilardini Montani MS *et al.* Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21. IUBMB life 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33987937>
 21. Amor F, Vu Hong A, Corre G *et al.* Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. Journal of cachexia, sarcopenia and muscle 2021; 12:677-693. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34037326>
 22. Chong D, Chen Z, Guan S *et al.* Geranylgeranyl pyrophosphate-mediated protein geranylgeranylation regulates endothelial cell proliferation and apoptosis during vasculogenesis in mouse embryo. Journal of genetics and genomics = Yi chuan xue bao 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34049800>
 23. Lee SH, Shin HS, Oh I. The Protective Effects of Statins Towards Vessel Wall Injury Caused by a Stent Retrieving Mechanical Thrombectomy Device : A Histological Analysis of the Rabbit Carotid Artery Model. Journal of Korean Neurosurgical Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33985322>
 24. Watanabe LM, Hashimoto AC, Torres DJ *et al.* Effect of statin treatment in obese selenium-supplemented mice lacking selenocysteine lyase. Molecular and cellular endocrinology 2021; 533:111335. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34052303>
 25. Ni W, Mo H, Liu Y *et al.* Targeting Cholesterol Biosynthesis Promotes Anti-tumor Immunity by Inhibiting Long Noncoding RNA SNHG29 Mediated YAP Activation. Molecular therapy : the journal of the American Society of Gene Therapy 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33992804>
 26. Xu Y, Dong Y, Wang C *et al.* Lovastatin attenuates sevoflurane-induced cognitive disorder in aged rats via reducing A β accumulation. Neurochem Int 2021; 148:105078. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34048842>
 27. Ha HS, Kim TY, Han SJ *et al.* Anti-atherosclerotic vaccination against *Porphyromonas gingivalis* as a potential comparator of statin in mice. PeerJ 2021; 9:e11293. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33976982>
 28. Patel O, Muller CJF, Joubert E *et al.* Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice. PLoS One 2021; 16:e0251069. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33983968>
 29. Aschenbrenner B, Negro G, Savic D *et al.* Simvastatin is effective in killing the radioresistant breast carcinoma cells. Radiol Oncol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33939900>
 30. Tripaldi R, Lanuti P, Simeone PG *et al.* Endogenous PCSK9 may influence circulating CD45(neg)/CD34(bright) and CD45(neg)/CD34(bright)/CD146(neg) cells in patients with type 2 diabetes mellitus. Scientific reports 2021; 11:9659. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33958634>
 31. Omer L, Hudson EA, Hudgins LC, Boyd NL. Cohort Generation and Characterization of Patient-Specific Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Stem Cells Dev 2021; 30:632-640. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34029164>

32. Zhang KL, Zhu WW, Wang SH *et al.* Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. *Theranostics* 2021; 11:6560-6572.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33995676>
33. Nagayama D, Saiki A, Shirai K. The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study. *Vasc Health Risk Manag* 2021; 17:169-173. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953560>

Cancer

1. Lopez DS, Huang D, Tsilidis KK *et al.* The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer. *Cancer Causes Control* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34041642>
2. Jeong IG, Lim B, Yun SC *et al.* Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial. *Clin Cancer Res* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34011557>
3. Anno T, Yamatsuji T, Tomoda K *et al.* Case Report: Various Abnormalities in Lipid and Glucose Metabolism Induced by Capecitabine. *Frontiers in oncology* 2021; 11:664475. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34017685>
4. Hu Z, Cheng C, Wang Y *et al.* Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. *Frontiers in oncology* 2021; 11:595285. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34041015>
5. Ni W, Mo H, Liu Y *et al.* Targeting Cholesterol Biosynthesis Promotes Anti-tumor Immunity by Inhibiting Long Noncoding RNA SNHG29 Mediated YAP Activation. *Molecular therapy : the journal of the American Society of Gene Therapy* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33992804>
6. Aschenbrenner B, Negro G, Savic D *et al.* Simvastatin is effective in killing the radioresistant breast carcinoma cells. *Radiol Oncol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33939900>
7. Hosio M, Urpilainen E, Hautakoski A *et al.* Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. *Scientific reports* 2021; 11:10445. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34001921>
8. Zhang KL, Zhu WW, Wang SH *et al.* Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. *Theranostics* 2021; 11:6560-6572. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33995676>
9. Nagayama D, Saiki A, Shirai K. The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study. *Vasc Health Risk Manag* 2021; 17:169-173. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953560>

Cost-effectiveness

1. Liang Z, Chen Q, Wei R *et al.* Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting. *Frontiers in pharmacology* 2021; 12:648244. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33935749>

CVD

1. Tan H, Liu L, Zheng Q *et al.* Effects of Combined Lipid-Lowering Therapy on Low-Density Lipoprotein Cholesterol Variability and Cardiovascular Adverse Events in Patients with Acute Coronary Syndrome. *Adv Ther* 2021; 38:3389-3398. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34018147>
2. Zanchin C, Koskinas KC, Ueki Y *et al.* Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. *Am Heart J* 2021; 238:33-44. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33951415>
3. Amarenco P, Kim JS, Labreuche J *et al.* Impact of lower vs higher LDL cholesterol targets on cardiovascular events after ischemic stroke in diabetic patients. *Diabetes* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980690>
4. R CV, Rajkumar Y, Vetriselvan P *et al.* Resveratrol-mediated cardioprotection against myocardial ischemia-reperfusion injury was revoked by statin-induced mitochondrial alterations. *Drug and chemical toxicology* 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34039170>
5. Olesen KKW, Heide-Jørgensen U, Thim T *et al.* Statin but not Aspirin Treatment is Associated with Reduced Cardiovascular Risk in Patients with Diabetes without Obstructive Coronary Artery Disease. *European heart journal. Cardiovascular pharmacotherapy* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33989394>
6. Anderson JLC, van der Giet M, Gomes Neto AW *et al.* Statin use and incident cardiovascular events in renal transplant recipients. *European journal of clinical investigation* 2021:e13594. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34042174>
7. Komajda M, Cosentino F, Ferrari R *et al.* Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. *Eur J Prev Cardiol* 2021; 28:432-445. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966083>
8. Barrios V, Escobar C. Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk. *Expert Rev Clin Pharmacol* 2021:1-14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33970743>
9. Møller PL, Rohde PD, Winther S *et al.* Sortilin as a Biomarker for Cardiovascular Disease Revisited. *Frontiers in cardiovascular medicine* 2021; 8:652584. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33937362>
10. Liang Z, Chen Q, Wei R *et al.* Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese

- Setting. Frontiers in pharmacology 2021; 12:648244.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33935749>
11. Wada H, Ogita M, Suwa S *et al.* Long-Term Clinical Impact of Cardiogenic Shock and Heart Failure on Admission for Acute Myocardial Infarction. Int Heart J 2021; 62:520-527. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33994511>
 12. Santoso A, Yulianto Y, Simarmata H *et al.* Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Int J Angiol 2021; 30:22-28.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34025093>
 13. Piri R, Lici G, Riyahimanesh P *et al.* Two-year change in 18F-sodium fluoride uptake in major arteries of healthy subjects and angina pectoris patients. The international journal of cardiovascular imaging 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33950330>
 14. Kanda D, Miyata M, Ikeda Y *et al.* The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34039817>
 15. Yao H, Farnier M, Tribouillard L *et al.* Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey. Lipids Health Dis 2021; 20:45.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33947397>
 16. Huang Q, Wang WT, Wang SS *et al.* Cardiovascular magnetic resonance image analysis and mechanism study for the changes after treatments for primary microvascular angina pectoris. Medicine (Baltimore) 2021; 100:e26038.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34032727>
 17. Ding HS, Yang J, Yang J *et al.* Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway. Molecular biology reports 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34032975>
 18. Yoshida K, Uwano I, Sasaki M *et al.* Small Unruptured Aneurysm Verification-prevention Effect against Growth of Cerebral Aneurysm Study Using Statin. Neurol Med Chir (Tokyo) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34024878>
 19. Bosch J, Lonn EM, Dagenais GR *et al.* Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke 2021:Strokeaha120030790.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33985364>
 20. Yang HX, Zuo HJ, Jia SJ *et al.* (Gender differences in risk factors and characteristics of young patients hospitalized for first acute coronary syndrome). Zhonghua yi xue za zhi 2021; 101:1403-1409.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34034368>

Endothelium/inflammation

1. R CV, Rajkumar Y, Vetrivelan P *et al.* Resveratrol-mediated cardioprotection against myocardial ischemia-reperfusion injury was revoked by statin-induced mitochondrial alterations. Drug and chemical toxicology 2021:1-9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34039170>
2. Huang Q, Wang WT, Wang SS *et al.* Cardiovascular magnetic resonance image analysis and mechanism study for the changes after treatments for primary microvascular angina pectoris. Medicine (Baltimore) 2021; 100:e26038. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34032727>

Ethnicity

1. Lin TH, Lee WL, Lee WJ *et al.* Dyslipidemia, Not Inflammatory Markers or Adipokines, Contributes Significantly to a Higher SYNTAX Score in Stable Coronary Artery Disease (from the Taichung CAD Study). Acta Cardiologica Sinica 2021; 37:232-238. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33976506>
2. Keech AC, Oyama K, Sever PS *et al.* Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Circulation journal : official journal of the Japanese Circulation Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980763>
3. Wada H, Ogita M, Suwa S *et al.* Long-Term Clinical Impact of Cardiogenic Shock and Heart Failure on Admission for Acute Myocardial Infarction. Int Heart J 2021; 62:520-527. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33994511>
4. Aghasizadeh M, Bizhaem SK, Baniasadi M *et al.* Evaluation of LDL goal achievement in statin consumption, south east of Iran. Scientific reports 2021; 11:10786. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34031484>

FH

1. Reeskamp LF, Nurmohamed NS, Bom MJ *et al.* Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis 2021; 327:13-17. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34004483>
2. Tada H, Okada H, Nohara A *et al.* Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia. Circulation journal : official journal of the Japanese Circulation Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34011825>
3. Cohen H, Stefanutti C. Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents. Curr Atheroscler Rep 2021; 23:30. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33963467>
4. Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside. Drug design, development and therapy 2021; 15:1955-1963. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34007155>

5. Vuorio A, Kaste M, Kovanen PT. Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke. eNeurologicalSci 2021; 23:100344. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33937536>
6. Polychronopoulos G, Tzavelas M, Tziomalos K. Heterozygous familial hypercholesterolemia: prevalence and control rates. Expert review of endocrinology & metabolism 2021:1-5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33993819>
7. Yamashita S, Masuda D, Harada-Shiba M *et al.* Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980760>
8. Pek SLT, Yap F, Sreedharan AV *et al.* Persistent hypercholesterolemia in child with homozygous autosomal recessive hypercholesterolemia: A decade of lipid management. J Clin Lipidol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33994332>
9. Yao H, Farnier M, Tribouillard L *et al.* Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey. Lipids Health Dis 2021; 20:45. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33947397>
10. Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia. The Medical letter on drugs and therapeutics 2021; 63:66-67. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33976097>
11. Matta A, Bongard V, Bouisset F *et al.* Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. Medical science monitor : international medical journal of experimental and clinical research 2021; 27:e928784. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33958572>
12. Omer L, Hudson EA, Hudgins LC, Boyd NL. Cohort Generation and Characterization of Patient-Specific Familial Hypercholesterolemia Induced Pluripotent Stem Cells. Stem Cells Dev 2021; 30:632-640. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34029164>

Genetics

1. Cenarro A, Bea AM, Gracia-Rubio I, Civeira F. Dysbetalipoproteinemia and other lipid abnormalities related to apo E. Clin Investig Arterioscler 2021; 33 Suppl 2:50-55. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34006354>
2. Santoso A, Yulianto Y, Simarmata H *et al.* Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Int J Angiol 2021; 30:22-28. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34025093>

3. Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. Nat Rev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953382>

Guidelines

1. Collins D, Inglin L, Laatikainen T *et al.* Evaluation and pilot implementation of essential interventions for the management of hypertension and prevention of cardiovascular diseases in primary health care in the Republic of Tajikistan. BMC Health Serv Res 2021; 21:472. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34006266>
2. Lowenstern A, Li S, Navar AM *et al.* Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. Clin Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34008247>
3. López-Miranda J, Pedro-Botet J. Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needs. Clin Investig Arterioscler 2021; 33 Suppl 1:46-52. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966813>
4. Marco-Benedí V, Jarauta Simón E, Laclaustra Gimeno M, Civeira Murillo F. Nursing workload. Calculation of cardiovascular risk and therapeutic objectives. Clin Investig Arterioscler 2021; 33 Suppl 1:10-17. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966807>
5. Yamashita S, Masuda D, Harada-Shiba M *et al.* Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980760>
6. Steffens D, Bramlage P, Müller J *et al.* Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease. Open heart 2021; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34001653>

LDL- related parameters

1. Dagliati A, Peek N, Brinton RD, Geifman N. Sex and APOE genotype differences related to statin use in the aging population. Alzheimer's & dementia (New York, N. Y.) 2021; 7:e12156. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33969178>
2. Cao J, Remaley AT, Guan W *et al.* Performance of novel low-density lipoprotein-cholesterol calculation methods in predicting clinical and subclinical atherosclerotic cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2021; 327:1-4. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34004482>
3. Puato M, Zambon A, Nardin C *et al.* Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast

- Rice. Cardiovasc Ther 2021; 2021:5546800.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33976708>
4. Tada H, Okada H, Nohara A *et al*. Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia. Circulation journal : official journal of the Japanese Circulation Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34011825>
 5. Lowenstern A, Li S, Navar AM *et al*. Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. Clin Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34008247>
 6. Marco-Benedí V, Jarauta Simón E, Laclaustra Gimeno M, Civeira Murillo F. Nursing workload. Calculation of cardiovascular risk and therapeutic objectives. Clin Investig Arterioscler 2021; 33 Suppl 1:10-17. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966807>
 7. Amarenco P, Kim JS, Labreuche J *et al*. Impact of lower vs higher LDL cholesterol targets on cardiovascular events after ischemic stroke in diabetic patients. Diabetes 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980690>
 8. Shin J, Chung JW, Jang HS *et al*. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33978157>
 9. Brandt EJ, Brandt DJ, Desai NR *et al*. Association of vitamins, minerals, and lead with Lipoprotein(a) in a cross-sectional cohort of US adults. Int J Vitam Nutr Res 2021;1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34024154>
 10. Kuyama N, Kataoka Y, Takegami M *et al*. Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy. J Am Heart Assoc 2021; 10:e019525. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998287>
 11. Hirano T, Kodera R, Hirashima T *et al*. Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33952832>
 12. Kanda D, Miyata M, Ikeda Y *et al*. The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34039817>
 13. Yamashita S, Masuda D, Harada-Shiba M *et al*. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980760>
 14. Ikeda S, Shinohara K, Enzan N *et al*. Effectiveness of statin intensive therapy in type 2 diabetes mellitus with high visit-to-visit blood pressure variability. J Hypertens 2021; 39:1435-1443. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34001809>
 15. Ebert T, Qureshi AR, Lamina C *et al*. Time-dependent lipid profile inversely associates with mortality in hemodialysis patients - independent of inflammation/malnutrition. Journal of internal medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998741>

16. Matta A, Bongard V, Bouisset F *et al.* Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. Medical science monitor : international medical journal of experimental and clinical research 2021; 27:e928784. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33958572>
17. Imre E, Gunhan HG, Erel P, Ustay O. SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study. Minerva Endocrinol (Torino) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33979071>
18. Lucchi T. Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly. Minerva medica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33949178>
19. Steffens D, Bramlage P, Müller J *et al.* Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease. Open heart 2021; 8. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34001653>
20. Achard M, Buhayer A, Dobretz K *et al.* (Long-lasting LDL-C lowering: silence at last). Revue medicale suisse 2021; 17:1039-1046. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34042340>
21. Aghasizadeh M, Bizhaem SK, Baniasadi M *et al.* Evaluation of LDL goal achievement in statin consumption, south east of Iran. Scientific reports 2021; 11:10786. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34031484>
22. Dearborn-Tomazos JL, Hu X, Bravata DM *et al.* Deintensification or No Statin Treatment Is Associated With Higher Mortality in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke 2021:Strokeaha120030089. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34015937>

Lifestyle

1. Cao Y, Liu Y, Zhang T *et al.* Comparative Analysis on Single- and Multiherb Strategies in Coronary Artery Atherosclerosis Therapy. Cardiology research and practice 2021; 2021:6621925. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34012683>
2. Puato M, Zambon A, Nardin C *et al.* Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice. Cardiovasc Ther 2021; 2021:5546800. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33976708>
3. Eschenhagen T, Laufs U. Statins Do More Than Lower Cholesterol-Depending on What You Eat? Circulation 2021; 143:1793-1796. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33939531>
4. Brandt EJ, Brandt DJ, Desai NR *et al.* Association of vitamins, minerals, and lead with Lipoprotein(a) in a cross-sectional cohort of US adults. Int J Vitam Nutr Res 2021:1-12. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34024154>

Meta-analyses

1. Fan H, Zhou J, Yuan Z. Meta-Analysis Comparing the Effect of Combined Omega-3 + Statin Therapy Versus Statin Therapy Alone on Coronary Artery Plaques. Am J Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34049675>
2. Vahedian-Azimi A, Mohammadi SM, Heidari Beni F *et al.* Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Archives of medical science : AMS 2021; 17:579-595. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34025827>
3. Xu T, Wang Y, Yuan J, Chen Y. The Effect of Statin Treatment on Outcomes of Cardioembolic Stroke: A Systematic Review and Meta-Analysis of Real-World Studies. CNS drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34019256>
4. Guo Y, Zhu LH, Zhao K *et al.* Statin use for the prevention of seizure and epilepsy in the patients at risk: A systematic review and meta-analysis of cohort studies. Epilepsy research 2021; 174:106652. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33971584>
5. Shin J, Chung JW, Jang HS *et al.* Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33978157>
6. Wei H, Xin X, Zhang J *et al.* Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis of randomized controlled trials. Irish journal of medical science 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33999383>

Metabolic Syndrome - Diabetes

1. van Zelst CM, de Boer GM, Türk Y *et al.* Association between elevated serum triglycerides and asthma in patients with obesity: An explorative study. Allergy Asthma Proc 2021; 42:e71-e76. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980342>
2. Lorenzatti AJ, Monsalvo ML, López JAG *et al.* Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. Cardiovascular diabetology 2021; 20:94. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33941192>
3. Kim SW, Chen J, Wegener KJ *et al.* Improvement of Statin Utilization in Veterans With Diabetes Through Pharmacy Interventions. Clin Diabetes 2021; 39:215-219. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33981132>
4. Schrader S, Perfilyev A, Martinell M *et al.* Statin therapy is associated with epigenetic modifications in individuals with Type 2 diabetes. Epigenomics 2021; 13:919-925. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33947200>
5. Olesen KKW, Heide-Jørgensen U, Thim T *et al.* Statin but not Aspirin Treatment is Associated with Reduced Cardiovascular Risk in Patients with Diabetes without Obstructive Coronary Artery Disease. European heart journal. Cardiovascular pharmacotherapy 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33989394>

6. Zhao Y, Liu L, Yang S *et al.* Mechanisms of Atherosclerosis Induced by Postprandial Lipemia. Frontiers in cardiovascular medicine 2021; 8:636947. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33996937>
7. Nakayama A, Morita H, Kawahara T *et al.* Association between testosterone and lipid profiles under statin therapy and its clinical impact on the cardiovascular event risk. Heart Vessels 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34036416>
8. Purkiss SF, Keegel T, Vally H, Wollersheim D. Estimates of age specific death rates in people with diabetes and associated multimorbidity using Australian administrative pharmaceutical data. Int J Popul Data Sci 2021; 6:1414. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34007903>
9. Hitchen SA, Lan NSR, Ali US *et al.* Investigating the effect of an education program on diabetes and lipid lowering medication usage following coronary artery bypass graft surgery. Internal medicine journal 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34033208>
10. Ikeda S, Shinohara K, Enzan N *et al.* Effectiveness of statin intensive therapy in type 2 diabetes mellitus with high visit-to-visit blood pressure variability. J Hypertens 2021; 39:1435-1443. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34001809>
11. Imre E, Gunhan HG, Erel P, Ustay O. SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study. Minerva Endocrinol (Torino) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33979071>
12. Krysiak R, Szkróbka W, Okopień B. Correction to: The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome. Pharmacological reports : PR 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34036550>
13. Patel O, Muller CJF, Joubert E *et al.* Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice. PLoS One 2021; 16:e0251069. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33983968>
14. Tripaldi R, Lanuti P, Simeone PG *et al.* Endogenous PCSK9 may influence circulating CD45(neg)/CD34(bright) and CD45(neg)/CD34(bright)/CD146(neg) cells in patients with type 2 diabetes mellitus. Scientific reports 2021; 11:9659. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33958634>

New Treatments

1. Zanchin C, Koskinas KC, Ueki Y *et al.* Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. Am Heart J 2021; 238:33-44. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33951415>
2. Hardy J, Niman S, Pereira E *et al.* A Critical Review of the Efficacy and Safety of Inclisiran. Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33954930>

3. Lepor NE, Sun J, Canton G *et al.* Regression in carotid plaque lipid content and neovasculture with PCSK9 inhibition: A time course study. *Atherosclerosis* 2021; 327:31-38. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34038761>
4. Reeskamp LF, Nurmohamed NS, Bom MJ *et al.* Marked plaque regression in homozygous familial hypercholesterolemia. *Atherosclerosis* 2021; 327:13-17. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34004483>
5. Lorenzatti AJ, Monsalvo ML, López JAG *et al.* Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. *Cardiovascular diabetology* 2021; 20:94. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33941192>
6. Keech AC, Oyama K, Sever PS *et al.* Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. *Circulation journal : official journal of the Japanese Circulation Society* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980763>
7. Lowenstern A, Li S, Navar AM *et al.* Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. *Clin Cardiol* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34008247>
8. Lekuona I, Pintó X. Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials. *Clin Investig Arterioscler* 2021; 33 Suppl 1:58-64. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966815>
9. Masana Marín L, Plana Gil N. Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties. *Clin Investig Arterioscler* 2021; 33 Suppl 1:53-57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966814>
10. Alam U, Al-Bazz DY, Soran H. Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review. *Diabetes Ther* 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34037950>
11. Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside. *Drug design, development and therapy* 2021; 15:1955-1963. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34007155>
12. Polychronopoulos G, Tzavelas M, Tziomalos K. Heterozygous familial hypercholesterolemia: prevalence and control rates. *Expert review of endocrinology & metabolism* 2021:1-5. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33993819>
13. Zhao Y, Liu L, Yang S *et al.* Mechanisms of Atherosclerosis Induced by Postprandial Lipemia. *Frontiers in cardiovascular medicine* 2021; 8:636947. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33996937>
14. Liang Z, Chen Q, Wei R *et al.* Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting. *Frontiers in pharmacology* 2021; 12:648244. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33935749>
15. Hitchen SA, Lan NSR, Ali US *et al.* Investigating the effect of an education program on diabetes and lipid lowering medication usage following coronary artery bypass

- graft surgery. Internal medicine journal 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34033208>
16. Evinacumab (Evkeeza) for homozygous familial hypercholesterolemia. The Medical letter on drugs and therapeutics 2021; 63:66-67.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33976097>
 17. Matta A, Bongard V, Bouisset F *et al.* Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. Medical science monitor : international medical journal of experimental and clinical research 2021; 27:e928784. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33958572>
 18. Steffens D, Bramlage P, Müller J *et al.* Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease. Open heart 2021; 8.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34001653>
 19. Ha HS, Kim TY, Han SJ *et al.* Anti-atherosclerotic vaccination against *Porphyromonas gingivalis* as a potential comparator of statin in mice. PeerJ 2021; 9:e11293. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33976982>
 20. Achard M, Buhayer A, Dobretz K *et al.* (Long-lasting LDL-C lowering: silence at last). Revue medicale suisse 2021; 17:1039-1046.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34042340>
 21. Tripaldi R, Lanuti P, Simeone PG *et al.* Endogenous PCSK9 may influence circulating CD45(neg)/CD34(bright) and CD45(neg)/CD34(bright)/CD146(neg) cells in patients with type 2 diabetes mellitus. Scientific reports 2021; 11:9659.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33958634>
 22. Yu Q, Zheng H, Zhang Y. Inducible degrader of LDLR: A potential novel therapeutic target and emerging treatment for hyperlipidemia. Vascul Pharmacol 2021:106878.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34015522>

Other

1. van Zelst CM, de Boer GM, Türk Y *et al.* Association between elevated serum triglycerides and asthma in patients with obesity: An explorative study. Allergy Asthma Proc 2021; 42:e71-e76. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980342>
2. Byler J, Harrison R, Fell LL. Rhabdomyolysis Following Recovery from Severe COVID-19: A Case Report. Am J Case Rep 2021; 22:e931616.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33963170>
3. Vahedian-Azimi A, Mohammadi SM, Heidari Beni F *et al.* Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Archives of medical science : AMS 2021; 17:579-595.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34025827>
4. Goel R, Chandan JS, Thayakaran R *et al.* Reply to comments on 'Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Base Retrospective Cohort Study'. Arthritis & rheumatology (Hoboken, N.J.) 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34042302>

5. Ikari Y, Matsue Y, Torii S *et al.* Association Between Statin Use Prior to Admission and Lower Coronavirus Disease 2019 (COVID-19) Severity in Patients With Cardiovascular Disease or Risk Factors. Circulation journal : official journal of the Japanese Circulation Society 2021; 85:939-943.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33952833>
6. Vuorio A, Kaste M, Kovanen PT. Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke. eNeurologicalSci 2021; 23:100344. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33937536>
7. Alves M, Fernandes MA, Bahat G *et al.* Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications. Eur Geriatr Med 2021:1-15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34031865>
8. McConnell M, Mobley DJ, Gidal A, Nagy MW. Population Health Management during Student Pharmacist Introductory Experiential Education to Expand Clinical Pharmacist Impact. Innov Pharm 2019; 10.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34007583>
9. Talasaz AH, Sadeghipour P, Aghakouchakzadeh M *et al.* Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials. medRxiv 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33972948>
10. Cesaro A, Riccio C, Calabrò P. Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target. Monaldi Arch Chest Dis 2021; 91. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33942600>
11. Khirfan G, Li M, Wang X *et al.* Abnormal levels of apolipoprotein A-I in chronic thromboembolic pulmonary hypertension. Pulmonary circulation 2021; 11:20458940211010371. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33996028>

PAD and statins

1. Sucharitkul PPJ, Jones KL, Scott DJA, Bailey MA. Lipid Optimization in Lower Extremity Peripheral Arterial Disease. Annals of vascular surgery 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33951531>

Pleiotropic effects of statins

1. Dagliati A, Peek N, Brinton RD, Geifman N. Sex and APOE genotype differences related to statin use in the aging population. Alzheimer's & dementia (New York, N. Y.) 2021; 7:e12156. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33969178>
2. Costantine MM, West H, Wisner KL *et al.* A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. American journal of obstetrics and gynecology 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34033812>
3. Byth LA, Byth J. Topical simvastatin-cholesterol for disseminated superficial actinic porokeratosis: An open-label, split-body clinical trial. Australas J Dermatol 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34028808>

4. Kocak E, Nemetlu E, Kir S *et al.* Integrative proteomics and metabolomics approach to elucidate the antimicrobial effect of simvastatin on *Escherichia coli*. Biomedical chromatography : BMC 2021:e5180.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34043824>
5. Valencia DY, Habila M, McClelland DJ *et al.* Infection-associated biofilms and statins: protocol for systematic review. BMJ Open 2021; 11:e046290.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34035102>
6. Lopez DS, Huang D, Tsilidis KK *et al.* The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer. Cancer Causes Control 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34041642>
7. Barreto GE, Gonzalez J, Reiner Ž *et al.* In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). Chemico-biological interactions 2021:109528.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34022192>
8. Eschenhagen T, Laufs U. Statins Do More Than Lower Cholesterol-Depending on What You Eat? Circulation 2021; 143:1793-1796.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33939531>
9. Domech CR, Travieso JCF, Guridi ZD *et al.* Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol 2021; 7:55-65. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34027116>
10. Xu T, Wang Y, Yuan J, Chen Y. The Effect of Statin Treatment on Outcomes of Cardioembolic Stroke: A Systematic Review and Meta-Analysis of Real-World Studies. CNS drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34019256>
11. Silva Marques J, Ennis G, Venade G *et al.* Association of Statins With Functional Outcome and 30-Day Mortality in Patients With Intracerebral Hemorrhage. Cureus 2021; 13:e14421.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33987069>
12. Bravo M, Raurell I, Barberá A *et al.* Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH. Disease models & mechanisms 2021; 14. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34014280>
13. Dehnavi S, Kiani A, Sadeghi M *et al.* Targeting AMPK by Statins: A Potential Therapeutic Approach. Drugs 2021; 81:923-933.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33939118>
14. Rahmani Z, Karimpour Malekshah A, Zargari M, Talebpour Amiri F. Effect of prenatal exposure to Benzo(a)pyrene on ovarian toxicity and reproductive dysfunction: Protective effect of atorvastatin in the embryonic period. Environ Toxicol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33978294>
15. Schrader S, Perfilyev A, Martinell M *et al.* Statin therapy is associated with epigenetic modifications in individuals with Type 2 diabetes. Epigenomics 2021; 13:919-925. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33947200>
16. Guo Y, Zhu LH, Zhao K *et al.* Statin use for the prevention of seizure and epilepsy in the patients at risk: A systematic review and meta-analysis of cohort studies. Epilepsy research 2021; 174:106652.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33971584>

17. Gao X, Zhou J, Bian Y *et al.* Simvastatin intervention mitigates hypercholesterolemia-induced alveolar bone resorption in rats. Experimental and therapeutic medicine 2021; 21:628.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33936284>
18. Hu Z, Cheng C, Wang Y *et al.* Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. Frontiers in oncology 2021; 11:595285.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34041015>
19. Huang X, He W, Wang W *et al.* Toxicology and Pharmacokinetics Study of Intradiscal Injection of Simvastatin in Rabbits. Frontiers in pharmacology 2021; 12:582309. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33967746>
20. Zhang Y, Ma L, Lu E, Huang W. Atorvastatin Upregulates microRNA-186 and Inhibits the TLR4-Mediated MAPKs/NF- κ B Pathway to Relieve Steroid-Induced Avascular Necrosis of the Femoral Head. Frontiers in pharmacology 2021; 12:583975.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33995003>
21. Sobrin L, Yu Y, Han S *et al.* Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34050812>
22. Ghafarzadeh M, Shakarami A, Yari F, Marzban Rad Z. The role of anti-proliferative effects of atorvastatin on uterine fibroids: findings from a clinical study. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2021:1-4.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33960277>
23. Cheung KS, Mak LY, Lam LK *et al.* Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. Hepatology Int 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33988834>
24. Santarelli R, Pompili C, Gilardini Montani MS *et al.* Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21. IUBMB life 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33987937>
25. Amor F, Vu Hong A, Corre G *et al.* Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. Journal of cachexia, sarcopenia and muscle 2021; 12:677-693. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34037326>
26. Lindström I, Protto S, Khan N *et al.* STATIN USE, DEVELOPMENT OF SARCOPENIA AND LONG-TERM SURVIVAL AFTER ENDOVASCULAR AORTIC REPAIR. Journal of vascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34019985>
27. Frasco PE, Aqel B, Alvord JM *et al.* Statin therapy and the incidence of thromboembolism and vascular events following liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33964102>
28. Tessier CM, Polyzos SA, Athyros VG, Mantzoros CS. Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give

- the emperor a statin robe? Metabolism 2021;154796.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33989632>
29. Ding HS, Yang J, Yang J *et al.* Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway. Molecular biology reports 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34032975>
 30. Xu Y, Dong Y, Wang C *et al.* Lovastatin attenuates sevoflurane-induced cognitive disorder in aged rats via reducing A β accumulation. Neurochem Int 2021; 148:105078. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34048842>
 31. Škorňová I, Samoš M, Bolek T *et al.* Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation? Pharmacol Res Perspect 2021; 9:e00730. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33984191>
 32. Aschenbrenner B, Negro G, Savic D *et al.* Simvastatin is effective in killing the radioresistant breast carcinoma cells. Radiol Oncol 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33939900>
 33. Hosio M, Urpilainen E, Hautakoski A *et al.* Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific reports 2021; 11:10445.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34001921>
 34. Wang J, Weng J, Li H *et al.* Atorvastatin and growth, rupture of small unruptured intracranial aneurysm: results of a prospective cohort study. Therapeutic advances in neurological disorders 2021; 14:1756286420987939.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33953800>
 35. Nagayama D, Saiki A, Shirai K. The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study. Vasc Health Risk Manag 2021; 17:169-173. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953560>

Primary Prevention

1. Jhaveri A, Sibley RA, Spatz ES, Dodson J. Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty. Current cardiology reports 2021; 23:67. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33961154>
2. Bosch J, Lonn EM, Jung H *et al.* Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. Eur Heart J 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33963372>
3. Olesen KKW, Heide-Jørgensen U, Thim T *et al.* Statin but not Aspirin Treatment is Associated with Reduced Cardiovascular Risk in Patients with Diabetes without Obstructive Coronary Artery Disease. European heart journal. Cardiovascular pharmacotherapy 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33989394>
4. Liu K, Wilkins JT, Colangelo LA, Lloyd-Jones DM. Does Lowering Low-Density Lipoprotein Cholesterol With Statin Restore Low Risk in Middle-Aged Adults? Analysis of the Observational MESA Study. J Am Heart Assoc 2021; 10:e019695.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33998284>

5. Allan S, Pencina M, Thanassoulis G. Clinical reasoning and prevention of cardiovascular disease. *J Clin Lipidol* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33992590>

Registry data

1. Lin TH, Lee WL, Lee WJ *et al.* Dyslipidemia, Not Inflammatory Markers or Adipokines, Contributes Significantly to a Higher SYNTAX Score in Stable Coronary Artery Disease (from the Taichung CAD Study). *Acta Cardiologica Sinica* 2021; 37:232-238. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33976506>
2. Cao J, Remaley AT, Guan W *et al.* Performance of novel low-density lipoprotein-cholesterol calculation methods in predicting clinical and subclinical atherosclerotic cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2021; 327:1-4.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34004482>
3. Lowenstern A, Li S, Navar AM *et al.* Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. *Clin Cardiol* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34008247>
4. Silva Marques J, Ennis G, Venade G *et al.* Association of Statins With Functional Outcome and 30-Day Mortality in Patients With Intracerebral Hemorrhage. *Cureus* 2021; 13:e14421.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33987069>
5. Komajda M, Cosentino F, Ferrari R *et al.* Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. *Eur J Prev Cardiol* 2021; 28:432-445.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33966083>
6. Gitsels LA, Bakbergenuly I, Steel N, Kulinskaya E. Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records. *Fam Med Community Health* 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34031184>
7. Sobrin L, Yu Y, Han S *et al.* Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database. *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34050812>
8. Cheung KS, Mak LY, Lam LK *et al.* Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. *Hepatol Int* 2021.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33988834>
9. Wada H, Ogita M, Suwa S *et al.* Long-Term Clinical Impact of Cardiogenic Shock and Heart Failure on Admission for Acute Myocardial Infarction. *Int Heart J* 2021; 62:520-527. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33994511>
10. Liu K, Wilkins JT, Colangelo LA, Lloyd-Jones DM. Does Lowering Low-Density Lipoprotein Cholesterol With Statin Restore Low Risk in Middle-Aged Adults?

- Analysis of the Observational MESA Study. J Am Heart Assoc 2021; 10:e019695. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998284>
11. Lindström I, Protto S, Khan N *et al*. STATIN USE, DEVELOPMENT OF SARCOPENIA AND LONG-TERM SURVIVAL AFTER ENDOVASCULAR AORTIC REPAIR. Journal of vascular surgery 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34019985>
 12. Frasco PE, Aqel B, Alvord JM *et al*. Statin therapy and the incidence of thromboembolism and vascular events following liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33964102>
 13. Borne E, Meyer N, Blanchard O *et al*. Statin (mis)use in older people: A cross-sectional study using French health insurance databases. Pharmacoepidemiol Drug Saf 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33949722>
 14. Hosio M, Urpilainen E, Hautakoski A *et al*. Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific reports 2021; 11:10445. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34001921>

Renal Disease

1. Anderson JLC, van der Giet M, Gomes Neto AW *et al*. Statin use and incident cardiovascular events in renal transplant recipients. European journal of clinical investigation 2021:e13594. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34042174>
2. Ebert T, Qureshi AR, Lamina C *et al*. Time-dependent lipid profile inversely associates with mortality in hemodialysis patients - independent of inflammation/malnutrition. Journal of internal medicine 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998741>
3. Abdelnabi M, Eshak N, Almaghraby A *et al*. Usefulness of statins in end-stage renal disease. Proceedings (Baylor University Medical Center) 2021; 34:361-363. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953460>

Reviews

1. Hardy J, Niman S, Pereira E *et al*. A Critical Review of the Efficacy and Safety of Inclisiran. Am J Cardiovasc Drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33954930>
2. Anagnostis P, Papanikolaou D, Ioannidou PG *et al*. The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review. Andrology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998174>
3. Cenarro A, Bea AM, Gracia-Rubio I, Civeira F. Dysbetalipoproteinemia and other lipid abnormalities related to apo E. Clin Investig Arterioscler 2021; 33 Suppl 2:50-55. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34006354>

4. Lekuona I, Pintó X. Clinical development of bempedoic acid: phase 2 and phase 3 clinical trials. Clin Investig Arterioscler 2021; 33 Suppl 1:58-64.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33966815>
5. Masana Marín L, Plana Gil N. Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties. Clin Investig Arterioscler 2021; 33 Suppl 1:53-57. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966814>
6. Mostaza JM, Lahoz C. Main barriers in the management of dyslipidaemias: Intolerants. Clin Investig Arterioscler 2021; 33 Suppl 1:40-45.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33966812>
7. Cohen H, Stefanutti C. Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents. Curr Atheroscler Rep 2021; 23:30. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33963467>
8. Alam U, Al-Bazz DY, Soran H. Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review. Diabetes Ther 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34037950>
9. Dehnavi S, Kiani A, Sadeghi M *et al.* Targeting AMPK by Statins: A Potential Therapeutic Approach. Drugs 2021; 81:923-933.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33939118>
10. Barankay I, Reese PP, Putt ME *et al.* Qualitative Exploration of Barriers to Statin Adherence and Lipid Control: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open 2021; 4:e219211.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33944923>
11. Statin-Associated Muscle Symptoms. Med Sci Sports Exerc 2020; 52:2489.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33956719>
12. Tessier CM, Polyzos SA, Athyros VG, Mantzoros CS. Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe? Metabolism 2021:154796.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33989632>
13. Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. Nat Rev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953382>
14. Abdelnabi M, Eshak N, Almaghraby A *et al.* Usefulness of statins in end-stage renal disease. Proceedings (Baylor University. Medical Center) 2021; 34:361-363.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33953460>
15. Achard M, Buhayer A, Dobretz K *et al.* (Long-lasting LDL-C lowering: silence at last). Revue medicale suisse 2021; 17:1039-1046.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34042340>
16. Tsu LV, Carroll K, Kindler K, Early N. Pharmacological Management of Hyperlipidemia in Older individuals. The Senior care pharmacist 2021; 36:284-303.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=34016226>

Safety and side effects

1. Mitaritunno M, Lupo M, Greco I *et al.* Severe rhabdomyolysis induced by co-administration of cocaine and heroin in a 45 years old man treated with

- rosuvastatin: a case report. Acta bio-medica : Atenei Parmensis 2021; 92:e2021089. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33944852>
2. Byler J, Harrison R, Fell LL. Rhabdomyolysis Following Recovery from Severe COVID-19: A Case Report. Am J Case Rep 2021; 22:e931616. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33963170>
 3. Anagnostis P, Papanikolaou D, Ioannidou PG *et al.* The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review. Andrology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998174>
 4. Vahedian-Azimi A, Makvandi S, Banach M *et al.* Fetal toxicity associated with statins: A systematic review and meta-analysis. Atherosclerosis 2021; 327:59-67. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34044205>
 5. Sabanis N, Paschou E, Drylli A *et al.* Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt. CEN Case Rep 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34028728>
 6. Frasson E, Simonetto M, Bertolasi L *et al.* Statin-associated necrotizing autoimmune myopathy with concurrent myasthenia gravis. Clinical case reports 2021; 9:e03925. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34026125>
 7. Mostaza JM, Lahoz C. Main barriers in the management of dyslipidaemias: Intolerants. Clin Investiq Arterioscler 2021; 33 Suppl 1:40-45. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966812>
 8. Filppula AM, Hirvensalo P, Parviainen H *et al.* Comparative hepatic and intestinal metabolism and pharmacodynamics of statins. Drug metabolism and disposition: the biological fate of chemicals 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34045219>
 9. Liuzzo G, Patrono C. StatinWISE sheds new light on statin-related muscle symptoms. Eur Heart J 2021; 42:1726-1727. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33961023>
 10. Li Z, Lyu Y, Zhao J *et al.* Disease Status-Dependent Drug-Herb Interactions: NASH Lowered the Risk of Hepatotoxicity in Rats Coadministered With Simvastatin and Gardenia jasminoides J. Ellis. Frontiers in pharmacology 2021; 12:622040. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33967756>
 11. Ooi BNS, Raechell, Ying AF *et al.* Robust Performance of Potentially Functional SNPs in Machine Learning Models for the Prediction of Atorvastatin-Induced Myalgia. Frontiers in pharmacology 2021; 12:605764. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33967749>
 12. Nakayama A, Morita H, Kawahara T *et al.* Association between testosterone and lipid profiles under statin therapy and its clinical impact on the cardiovascular event risk. Heart Vessels 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34036416>
 13. Santoso A, Yulianto Y, Simarmata H *et al.* Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Int J Angiol 2021; 30:22-28. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34025093>

14. Hoskins MJ, Richards S. Statin-induced liver dysfunction triggering fatal myonecrosis. Internal medicine journal 2021; 51:812-813. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34047026>
15. Wei H, Xin X, Zhang J *et al.* Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis of randomized controlled trials. Irish journal of medical science 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33999383>
16. Saha A, Garg A. Severe Liver Injury Associated With High-Dose Atorvastatin Therapy. Journal of investigative medicine high impact case reports 2021; 9:23247096211014050. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33966478>
17. Hou Y, Shao K, Yan Y *et al.* Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy. Journal of neurology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34021410>
18. Statin-Associated Muscle Symptoms. Med Sci Sports Exerc 2020; 52:2489. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33956719>
19. Ortland I, Mirjalili M, Kullak-Ublick GA, Peymani P. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase™ from 2010 to 2020. Swiss Med Wkly 2021; 151:w20503. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34000058>

Stroke and CNS

1. Klein J, Mauck L, Schackert G, Pinzer T. Do statins reduce the rate of revision surgery after chronic subdural hematoma drain? Acta neurochirurgica 2021; 163:1843-1848. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34036461>
2. Dagliati A, Peek N, Brinton RD, Geifman N. Sex and APOE genotype differences related to statin use in the aging population. Alzheimer's & dementia (New York, N. Y.) 2021; 7:e12156. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33969178>
3. Xu T, Wang Y, Yuan J, Chen Y. The Effect of Statin Treatment on Outcomes of Cardioembolic Stroke: A Systematic Review and Meta-Analysis of Real-World Studies. CNS drugs 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34019256>
4. Silva Marques J, Ennis G, Venade G *et al.* Association of Statins With Functional Outcome and 30-Day Mortality in Patients With Intracerebral Hemorrhage. Cureus 2021; 13:e14421. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33987069>
5. Amarenco P, Kim JS, Labreuche J *et al.* Impact of lower vs higher LDL cholesterol targets on cardiovascular events after ischemic stroke in diabetic patients. Diabetes 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980690>
6. Vuorio A, Kaste M, Kovanen PT. Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke. eNeurologicalSci 2021; 23:100344. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33937536>
7. Guo Y, Zhu LH, Zhao K *et al.* Statin use for the prevention of seizure and epilepsy in the patients at risk: A systematic review and meta-analysis of cohort studies. Epilepsy research 2021; 174:106652. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33971584>

8. Shin J, Chung JW, Jang HS *et al.* Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33978157>
9. Satani N, Zhang X, Giridhar K *et al.* A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro. Frontiers in pharmacology 2021; 12:589418. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33959001>
10. Komatsu T, Ayaori M, Uto-Kondo H *et al.* Atorvastatin Reduces Circulating S100A12 Levels in Patients with Carotid Atherosclerotic Plaques - A Link with Plaque Inflammation. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33952812>
11. Xu Y, Dong Y, Wang C *et al.* Lovastatin attenuates sevoflurane-induced cognitive disorder in aged rats via reducing A β accumulation. Neurochem Int 2021; 148:105078. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34048842>
12. Bosch J, Lonn EM, Dagenais GR *et al.* Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke 2021:Strokeaha120030790. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33985364>
13. Dearborn-Tomazos JL, Hu X, Bravata DM *et al.* Deintensification or No Statin Treatment Is Associated With Higher Mortality in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke 2021:Strokeaha120030089. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34015937>
14. Wang J, Weng J, Li H *et al.* Atorvastatin and growth, rupture of small unruptured intracranial aneurysm: results of a prospective cohort study. Therapeutic advances in neurological disorders 2021; 14:1756286420987939. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953800>

Triglycerides/HDL

1. van Zelst CM, de Boer GM, Türk Y *et al.* Association between elevated serum triglycerides and asthma in patients with obesity: An explorative study. Allergy Asthma Proc 2021; 42:e71-e76. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980342>
2. Zhao Y, Liu L, Yang S *et al.* Mechanisms of Atherosclerosis Induced by Postprandial Lipemia. Frontiers in cardiovascular medicine 2021; 8:636947. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33996937>
3. Selvaraj S, Claggett BL, Packer M *et al.* Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure with Preserved Ejection Fraction. J Am Heart Assoc 2021:e022069. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998278>
4. Hirano T, Kodera R, Hirashima T *et al.* Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33952832>
5. Ebert T, Qureshi AR, Lamina C *et al.* Time-dependent lipid profile inversely associates with mortality in hemodialysis patients - independent of

inflammation/malnutrition. Journal of internal medicine 2021.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33998741>

Trials

1. Zanchin C, Koskinas KC, Ueki Y *et al*. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. Am Heart J 2021; 238:33-44. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33951415>
2. Costantine MM, West H, Wisner KL *et al*. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. American journal of obstetrics and gynecology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34033812>
3. Lepor NE, Sun J, Canton G *et al*. Regression in carotid plaque lipid content and neovasculture with PCSK9 inhibition: A time course study. Atherosclerosis 2021; 327:31-38. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34038761>
4. Byth LA, Byth J. Topical simvastatin-cholesterol for disseminated superficial actinic porokeratosis: An open-label, split-body clinical trial. Australas J Dermatol 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34028808>
5. Keech AC, Oyama K, Sever PS *et al*. Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Circulation journal : official journal of the Japanese Circulation Society 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33980763>
6. Jeong IG, Lim B, Yun SC *et al*. Adjuvant Low-dose Statin Use after Radical Prostatectomy: The PRO-STAT Randomized Clinical Trial. Clin Cancer Res 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34011557>
7. Domech CR, Travieso JCF, Guridi ZD *et al*. Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol 2021; 7:55-65. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34027116>
8. Bosch J, Lonn EM, Jung H *et al*. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. Eur Heart J 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33963372>
9. Liuzzo G, Patrono C. StatinWISE sheds new light on statin-related muscle symptoms. Eur Heart J 2021; 42:1726-1727. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33961023>
10. Camila de Souza Groia Veloso R, Cruzeiro MGM, Dias BM, Reis AMM. Assessment of adherence to statin therapy in patients with coronary artery disease: comparison of three self-reporting measures. Eur J Hosp Pharm 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34031152>

11. S WC, G KG, B ME. Assessment of Patient Education about Statin Therapy on Quality Measures and Knowledge in an Independent Community Pharmacy. Innov Pharm 2019; 10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34007557>
12. Kuyama N, Kataoka Y, Takegami M *et al.* Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy. J Am Heart Assoc 2021; 10:e019525. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33998287>
13. Komatsu T, Ayaori M, Uto-Kondo H *et al.* Atorvastatin Reduces Circulating S100A12 Levels in Patients with Carotid Atherosclerotic Plaques - A Link with Plaque Inflammation. J Atheroscler Thromb 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33952812>
14. Yoshida K, Uwano I, Sasaki M *et al.* Small Unruptured Aneurysm Verification-prevention Effect against Growth of Cerebral Aneurysm Study Using Statin. Neurol Med Chir (Tokyo) 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34024878>
15. Škorňová I, Samoš M, Bolek T *et al.* Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation? Pharmacol Res Perspect 2021; 9:e00730. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33984191>
16. Bosch J, Lonn EM, Dagenais GR *et al.* Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke 2021:Strokeaha120030790. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33985364>
17. Wang J, Weng J, Li H *et al.* Atorvastatin and growth, rupture of small unruptured intracranial aneurysm: results of a prospective cohort study. Therapeutic advances in neurological disorders 2021; 14:1756286420987939. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33953800>

Women and elderly

1. Costantine MM, West H, Wisner KL *et al.* A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. American journal of obstetrics and gynecology 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34033812>
2. Vahedian-Azimi A, Makvandi S, Banach M *et al.* Fetal toxicity associated with statins: A systematic review and meta-analysis. Atherosclerosis 2021; 327:59-67. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34044205>
3. Jhaveri A, Sibley RA, Spatz ES, Dodson J. Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty. Current cardiology reports 2021; 23:67. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33961154>
4. de Barros JWF, Villela ESP, da Silva GV *et al.* Rosuvastatin exposure in female Wistar rats alters uterine contractility and do not show evident (anti)estrogenic effects. Drug and chemical toxicology 2021:1-13. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33934680>
5. Alves M, Fernandes MA, Bahat G *et al.* Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications. Eur Geriatr Med 2021:1-15. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34031865>

6. Gitsels LA, Bakbergenuly I, Steel N, Kulinskaya E. Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records. Fam Med Community Health 2021; 9. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34031184>
7. Lucchi T. Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly. Minerva medica 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33949178>
8. Borne E, Meyer N, Blanchard O *et al.* Statin (mis)use in older people: A cross-sectional study using French health insurance databases. Pharmacoepidemiol Drug Saf 2021. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33949722>
9. Tsu LV, Carroll K, Kindler K, Early N. Pharmacological Management of Hyperlipidemia in Older individuals. The Senior care pharmacist 2021; 36:284-303. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34016226>
10. Yang HX, Zuo HJ, Jia SJ *et al.* (Gender differences in risk factors and characteristics of young patients hospitalized for first acute coronary syndrome). Zhonghua yi xue za zhi 2021; 101:1403-1409. <http://www.ncbi.nlm.nih.gov/pubmed/?term=34034368>